HED与NH3动力学定量是否改善缺血性心肌病风险分层
本研究为PAREPET前瞻性试验的子分析,纳入174例LVEF≤35%的缺血性心肌病患者,比较[11C]HED与[13N]NH3的常规摄取与参数化动力学分析对SCA风险的判别能力。随访4.1年发生27例SCA事件,参数化或摄取不匹配的AUC为0.73或0.70,较HED摄取缺损评分AUC=0.67未显著改善风险分层。
要点
- HED缺损大于NH3缺损,尤其在灌注异常最低三分位组(P<.001)。
- 参数化缺损大于各自示踪剂摄取缺损(P<.001)。
- 参数化或不匹配分析未显著改善SCA风险判别(AUC 0.73/0.70 vs 0.67)。
核心结论
- HED分布体积与NH3心肌血流的定量产生比各自示踪剂摄取更大的缺损,但未较HED摄取单独分析改善SCA风险分层。
研究设计与样本
- 前瞻性PAREPET试验的子分析,纳入LVEF≤35%的缺血性心肌病患者,使用174对动态HED与NH3 PET扫描。
主要发现
- 随访4.1年发生27例SCA事件。
- HED缺损大于NH3缺损,尤其在灌注异常最低三分位组(P<.001)。
- 参数化缺损大于各自示踪剂摄取缺损(P<.001)。
- 参数化或摄取不匹配的SCA风险判别AUC=0.73或0.70,HED摄取缺损评分AUC=0.67。
关键数值与推荐
- 区域缺损评分按%LV范围×严重程度计算,使用HED与NH3摄取以及动力学建模的HED分布体积和NH3心肌血流。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In ischemic cardiomyopathy patients, cardiac sympathetic nervous system dysfunction is a predictor of sudden cardiac arrest (SCA). This study compared abnormal innervation and perfusion measured by [11C]meta-hydroxyephedrine (HED) vs [13N]ammonia (NH3), conventional uptake vs parametric tracer analysis, and their SCA risk discrimination. METHODS: This is a sub-study analysis of the prospective PAREPET trial, which followed ischemic cardiomyopathy patients with reduced left ventricular ejection fraction (LVEF ≤ 35%) for events of SCA. Using n = 174 paired dynamic HED and NH3 positron emission tomography (PET) scans, regional defect scores (%LV extent × severity) were calculated using HED and NH3 uptake, as well as HED distribution volume and NH3 myocardial blood flow by kinetic modeling. RESULTS: During 4.1 years follow-up, there were 27 SCA events. HED defects were larger than NH3, especially in the lowest tertile of perfusion abnormality (P < .001). Parametric defects were larger than their respective tracer uptake defects (P < .001). SCA risk discrimination was not significantly improved with parametric or uptake mismatch (AUC = 0.73 or 0.70) compared to HED uptake defect scores (AUC = 0.67). CONCLUSION: Quantification of HED distribution volume and NH3 myocardial blood flow produced larger defects than their respective measures of tracer uptake, but did not lead to improved SCA risk stratification vs HED uptake alone.
引用
- Wang JZ, Zelt JGE, Kaps N, et al. Does quantification of [11C]meta-hydroxyephedrine and [13N]ammonia kinetics improve risk stratification in ischemic cardiomyopathy. J Nucl Cardiol. 2021. PMID: 34341953. doi:10.1007/s12350-021-02732-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。